Drugs / DERMASEAL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05586542 | Oct 2022 → Mar 2025 overdue | ulcer of lower limbs | Vitruvian Medical Devices, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06134843 | Sep 2024 → Jan 2025 | — | Hobart W. Harris | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DERMASEAL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06134843 ↗ |
| Route | Topical | “Place an appropriately sized piece of DERMASEAL onto the wound bed.” NCT05586542 ↗ |